-- Sportradar Group (SRAD) has an average rating of buy and mean price target of $22.88 according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $12.64, Change: $+0.29, Percent Change: +2.31%
AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected first-quarter results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs.Per-share adjusted earnings are expected at $14.08 to $14.28 for 2026, up from prior guidance of $13.96 to $14.16. The guidance includes $0.41 in expenses related to acquired in-process research and development and milestone expenses in the first quarter. The current consensus on FactSet is for non-GAAP EPS of $14.12.AbbVie now expects revenue of about $67.3 billion for the current year, an increase of $300 million, Chief Financial Officer Scott Reents said during an earnings call, according to a FactSet transcript. The Street is looking for $67.07 billion.The company's shares rose 0.9% in Wednesday trading. The stock has dropped 13% this year.For the March quarter, the company reported adjusted EPS of $2.65, up from $2.46 a year earlier and ahead of the Wall Street estimate of $2.59. Revenue climbed 12% to $15 billion, surpassing the estimate on FactSet for $14.72 billion."We are off to an excellent start in 2026, with first-quarter results exceeding our expectations," CEO Robert Michael said in a statement. "AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook."Global sales from the immunology portfolio rose 16% to $7.29 billion. Gains of 31% for Skyrizi and 23% for Rinvoq helped counter a 39% drop for Humira. In the neuroscience segment, revenue jumped 26% to $2.89 billion, while oncology portfolio sales eased 0.2% to $1.63 billion.Revenue in the aesthetics portfolio increased 7.6% to $1.19 billion.AbbVie projects adjusted EPS of $3.74 to $3.78 in the current quarter on revenue of $16.7 billion, including a foreign-exchange gain of 0.6%, Reents said on the call. Analysts project non-GAAP EPS of $3.75 on sales of $16.8 billion.Price: $199.39, Change: $+1.70, Percent Change: +0.86%
The Bank of Canada's Governing Council left rates unchanged at 2.25% on Wednesday and signaled that elevated oil prices won't do much to boost gross domestic product or underlying inflationary pressures, said Desjardins.For its projections, the BoC assumed that Brent oil prices will fall to around US$75/barrel by mid-2027, roughly in line with the bank's forecasts.That said, policymakers expect investment and employment to be less responsive to higher crude prices than in the past, leaving real gross domestic product up just 1.2% in 2026, while previously it saw at 1.1%. So while the composition of growth will look different -- many households and businesses will be squeezed by higher energy costs even as some firms and governments benefit -- the economy is still expected to absorb slack only slowly this year, stated Desjardins.The good news is that officials share the bank's view that spillovers to core inflation will be limited. The BoC expects core inflation to end 2026 at 2.0%, which is actually a touch lower than the 2.1% penciled in back in January's Monetary Policy Report (MPR).The commentary accompanying the rate decision also highlighted the favorable starting point for underlying inflation, with the BoC's preferred core measures just slightly above 2% in March and the proportion of components rising above 3% also having declined in recent months. So while officials acknowledged the cost pressures associated with high oil prices, they implied that their operational target, underlying inflation, wouldn't be impacted, added the bank.Wednesday's MPR also included projections for an alternative scenario in which oil prices remain around US$100 per barrel. Even in that scenario, the economy is expected to struggle over the next few years, as many households and businesses would face higher costs and the benefits of elevated crude prices would translate into increased activity in oil-producing regions with a lag.That said, the forecasts include a further rise in headline inflation, which is substantially more persistent and broad-based than in the base case projections. Governor Tiff Macklem appears to suggest that such a situation could warrant consecutive increases in the policy rate, according to Desjardins.Overall, the BoC appears comfortable leaving rates unchanged for the rest of the year, unless oil prices remain high, added the bank. Assuming oil prices decline to levels consistent with their assumptions, the central bank's communications suggest that any changes in the target rate will be small.Desjardins takes that to mean that once the economy recovers to full health, central bankers will raise the policy rate gradually to 2.75%, the mid-point of their estimated neutral rate range. The bank's expectation is that those rate increases aren't in the cards until 2027.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AVT delivered a strong Q3 beat with revenue of $7.12B (+34% Y/Y, +13% Q/Q) vs. $6.4B consensus and adjusted EPS of $1.48 (+76% Y/Y, +41% Q/Q) vs. $1.32 consensus. Operating margins expanded to 2.9% (+58bps Q/Q) with Electronic Components achieving 3.5% margins, demonstrating quality operating leverage as sequential operating income grew more than twice as fast as sales. Broad-based strength across all regions Asia +39%, EMEA +31%, Americas +27% suggests a genuine demand recovery beyond AI infrastructure into traditional electronics markets. Q4 guidance of $7.30B-$7.60B sales (midpoint $7.45B) and adjusted EPS of $1.70-$1.80 significantly exceeded consensus of $6.5B revenue and $1.41 EPS. Inventory optimization reached management's target with total days declining to 77 days, enabling $800M sales growth with only $54M operating cash flow usage. We believe the inventory destocking cycle has conclusively ended and AVT is well-positioned to capitalize on the electronics market recovery with sustained momentum.